<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68701">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01762540</url>
  </required_header>
  <id_info>
    <org_study_id>GK_nilani_2012</org_study_id>
    <nct_id>NCT01762540</nct_id>
  </id_info>
  <brief_title>Glucocorticoid Induced Inhibition of IGF-I Activity: Exploring Underlying Mechanisms.</brief_title>
  <official_title>Glucocorticoid Induced Inhibition of IGF-I Activity: Exploring Underlying Mechanisms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ministry of Science, Technology and Innovation, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the trial is to advance our knowledge on the possible mechanism
      underlying the catabolic effects of long-term treatment with glucocorticoid. More
      specifically the investigators are interested in the molecular mechanisms by which
      glucocorticoid inhibits growth.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Insulin-like Growth Factor (IGF)-I profiles of subjects before and after prednisolone-treatment.</measure>
    <time_frame>day 1, 3 and 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood-test before (day 1) during (day 3) and at the end (day 5) of placebo/prednisolone treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracellular signaling of IGF-I under the influence/abscence of prednisolone.</measure>
    <time_frame>day 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tissue biopsy on day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity under the influence/abscence of prednisolone.</measure>
    <time_frame>Day 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hyperinsulinemic euglycemic clamp on day 5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Focus of Study: Prednisolone Induced Catabolic Effects</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed and dated informed consent

          -  healthy subjects

          -  sex: male

          -  age 20-30 years

          -  BMI 19-26 kg/m2

          -  normal HbA1c

        Exclusion Criteria:

          -  suspected og known allergy to the trial drug or similar medications.

          -  known current illness including diabetes mellitus, ischemic heart disease or cardiac
             arrhythmia.

          -  Daily drug intake (excluding Over-the-Counter medicines).

          -  Known or previous mental illness

          -  Current participation or previous participation in experiments using ionizing
             radiation for a year prior to inclusion in this study.

          -  Participation in a larger X-ray examinations in trial period.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Frystyk, Doctor, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research Laboratory, Clinical institute of Medicine, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nilani Ramshanker, Doctor</last_name>
    <phone>+45 78462154</phone>
    <email>nilani.ramshanker@ki.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Frystyk, Doctor</last_name>
    <phone>+45 89492166</phone>
    <email>jan.frystyk@ki.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Research Laboratory, Clinical Institute of Medicine, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilani Ramshanker, Doctor</last_name>
      <phone>+45 78462154</phone>
      <email>nilani.ramshanker@ki.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jan Frystyk, Doctor</last_name>
      <phone>+45 89492166</phone>
    </contact_backup>
    <investigator>
      <last_name>Nilani Ramshanker, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 4, 2013</lastchanged_date>
  <firstreceived_date>January 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Protein breakdown</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Glucose intolerance</keyword>
  <keyword>Lipolysis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
